Skip to content
Multidisciplinary Association for Psychedelic Studies – MAPS

Multidisciplinary Association for Psychedelic Studies - MAPS

  • About
    • Our Mission
    • Our History
    • Our Team
    • Financial Reports
    • Careers
  • Our Work
    • Psychedelic Fundamentals
    • MAPS Public Benefit Corp
    • MDMA Therapy Training
    • Zendo Project
    • Policy & Advocacy
    • Health Equity
  • Our Research
    • MDMA
    • Marijuana
    • LSD
    • Ibogaine
    • Ayahuasca
  • News
    • Updates
    • MAPS in the Media
    • MAPS Bulletin
    • MAPS Podcast
    • Monthly Newsletter
    • Press Releases
    • Newsroom
  • Take Action
    • Donate
    • Host a Party
    • Participate in Trial
    • Volunteer
    • Events
    • Resources
  • Store
    • Learning
    • Apparel
    • Accessories
    • Bookshop
    • 7 Principles
Login
  • Donate
0

Press Releases

MDMA-Assisted Group Therapy for PTSD Among Veterans Study Will Proceed Following Successful Safety Negotiations

The FDA lifted the clinical hold from a MAPS-sponsored Phase 2 study of MDMA-assisted group therapy for the treatment of posttraumatic stress disorder among veterans at the VA Portland Health Care System …
June 29, 2022

Novel PTSD Treatment Advances Toward Regulatory Evaluation with New Collaboration

On PTSD Awareness Day, MAPS PBC announces plans to develop the New Drug Application for MDMA-assisted therapy in collaboration with MMS Holdings The second Phase 3 trial of the Breakthrough-Designated …
June 27, 2022

MAPS Appoints Jeff George and Dan Grossman to MAPS PBC Board of Directors

Experienced healthcare leaders bring decades of experience in global drug commercialization and patient access Appointment brings significant pharmaceutical leadership experience to the MAPS PBC board …
June 7, 2022

Christie’s Announces Cartography of the Mind: A Curated NFT Sale to Benefit MAPS

Christie’s is pleased to present Cartography of the Mind, a Curated NFT Sale to benefit the Multidisciplinary Association for Psychedelic Studies (MAPS) in collaboration with Ryan Zurrer, founder of …
June 6, 2022

MAPS Completes Enrollment, as Planned, for the Confirmatory Phase 3 Trial of MDMA-Assisted Therapy for PTSD

FOR IMMEDIATE RELEASE: May 9, 2022 The second, confirmatory Phase 3 trial of MDMA-assisted therapy for PTSD is now fully enrolled at 13 sites in the United States and Israel Completion of enrollment on …
May 9, 2022

MAPS Places Fully Validated, Multi-Kilogram Synthesis MDMA in the Public Domain

MAPS and MAPS PBC have developed the first validated commercial synthetic process for producing multi-kilogram batches of MDMA under current Good Manufacturing Practices The availability of larger quantities …
April 5, 2022

Revised Edition of The Secret Chief Revealed: Conversations with Leo Zeff, Pioneer in the Underground Psychedelic Therapy Movement to publish April 19, 2022

The Multidisciplinary Association for Psychedelic Studies (MAPS) and Synergetic Press are breathing new life into a classic book that details the work of an underground psychedelic-assisted therapy trailblazer. …
March 30, 2022

Michael Mullette Joins MAPS PBC Senior Leadership as Chief Operating Officer

Former Moderna Vice President and Managing Director for North America recruited to prepare MAPS PBC for patient access and commercialization of the first psychedelic-assisted therapy anticipated to be …
March 8, 2022

atai Impact Donates to MAPS to Support Pioneering Work in Psychedelic Medicine

FOR IMMEDIATE RELEASE Leading non-profit and commercial organizations in psychedelic science united in visions to heal mental health conditions Donation is from atai Impact, the philanthropic arm of mental …
February 16, 2022

MAPS and MAPS PBC Publish Patient Bill of Rights for Psychedelic Therapy

Patient Bills of Rights are made available to patients in various settings across the mental health and medical fields to communicate clearly with patients about what they can expect from professionals …
February 10, 2022

MAPS PBC Adopts Charter for Independent Ethics Review Board

FOR IMMEDIATE RELEASE Independent members will inform continual iteration and improvement of ethical governance of MDMA-assisted therapy research and therapist training program Independent Ethical Review …
February 2, 2022

MAPS is Granted Innovation Passport in United Kingdom for MDMA as an Adjunct to Therapy for PTSD

FOR IMMEDIATE RELEASE MDMA as an adjunct to therapy for PTSD is the forty-first treatment to receive the Innovation Passport since its inception in January 2021 The designation is intended to accelerate …
January 25, 2022

Posts navigation

Newer Posts Page 1 Page 2 … Page 10 Older Posts
Multidisciplinary Association for Psychedelic Studies – MAPS
  • About
    • Our Mission
    • Our History
    • Our Team
    • Financial Reports
    • Careers
    • Refunds & Returns
    • FAQs
    • Privacy Policy
  • Our Work
    • Psychedelic Fundamentals
    • MAPS Public Benefit Corp
    • MDMA Therapy Training
    • Zendo Project
    • Health Equity
    • Policy & Advocacy
  • Our Research
    • MDMA
    • Marijuana
    • LSD
    • Ibogaine
    • Ayahuasca
  • News
    • Updates
    • MAPS in the Media
    • MAPS Bulletin
    • MAPS Podcast
    • Monthly Newsletter
    • Press Releases
    • Newsroom
  • Take Action
    • Donate
    • Host a Party
    • Participate in a Trial
    • Events
    • Resources

Newsletter Sign Up



  • Facebook
  • Instagram
  • Twitter
  • YouTube
  • LinkedIn
  • Reddit
© 1986 - 2022 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved. Disclaimer | Privacy Policy.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Proudly powered by WordPress. Hosted by Pressable.